RELAPSING MULTIPLE SCLEROSIS

This study followed 107 adults in Switzerland with relapsing multiple sclerosis who were already taking Kesimpta (ofatumumab) as part of their routine care. Researchers tracked how many patients had no signs of disease activity, including relapses, new brain lesions, or worsening…

This study looked at how well ofatumumab works in 562 people with relapsing multiple sclerosis who switched from other drugs (fumarates or fingolimod) because their disease was still active. The main goal was to see how many relapses they had per year. Researchers also tracked si…

This Phase 3 study tested whether ofatumumab, a monthly injection, works better than standard first-line disease-modifying therapies (like glatiramer acetate or interferon) in people newly diagnosed with relapsing multiple sclerosis. The main goal was to see if more patients coul…

This study followed 1,710 people with relapsing or primary progressive multiple sclerosis who were prescribed ocrelizumab (Ocrevus) as part of their normal care. Researchers tracked symptoms like fatigue, mobility, and cognition, as well as side effects, to see how well the drug …

This study looked at whether people with relapsing multiple sclerosis can safely switch from an intravenous (IV) anti-CD20 antibody treatment to a self-injected drug called ofatumumab. 111 adults took part, and researchers tracked their brain scans and side effects for a year. Th…

This study looked at how well and how safely the drug fingolimod (Gilenya) works for people in China with relapsing multiple sclerosis (RMS), a condition where the immune system attacks the nerves. Over 24 months, 98 participants took a daily 0.5 mg pill. The main goal was to see…

This study tested the drug ofatumumab in 99 Chinese adults with relapsing multiple sclerosis (RMS). The goal was to see if monthly injections could reduce the number of relapses and monitor for side effects. Participants received the drug for 12 months, and researchers tracked re…

This completed study looked at how well cladribine tablets work in everyday practice for people with relapsing multiple sclerosis (MS) who had a poor response to other oral or infusion treatments. Researchers tracked 291 participants over 24 months, measuring relapse rates and pa…

This phase 2 trial tested a liquid suspension of gold nanocrystals, called CNM-Au8, in 33 people with relapsing multiple sclerosis. The goal was to see if the treatment could improve energy metabolism in brain cells, measured by a special MRI scan. Participants took the drug by m…

This study tested the long-term safety of the drug SAR442168 in 125 people with relapsing multiple sclerosis who had already completed a previous study. Researchers monitored side effects and checked brain scans for disease activity over about 4.5 years. The goal was to see if th…

This phase 2b trial tested an experimental oral drug called SAR442168 in 130 adults with relapsing multiple sclerosis. The goal was to find the best dose to reduce new active brain lesions seen on MRI scans. Participants took the drug or a placebo for 12 to 16 weeks, and research…

This study followed 307 people with relapsing multiple sclerosis in Germany who had recently switched to the drug Kesimpta (ofatumumab) from another treatment. Researchers collected information on why patients made the switch and how many doses they missed over one year. The goal…

This study looked at how well people with relapsing multiple sclerosis (RMS) follow their Kesimpta (Ofatumumab) treatment plan. Researchers used data from the MSGo patient support app to track when doses were taken. They also compared how patients felt (reported symptoms) with th…

This study followed 10 adults with relapsing multiple sclerosis for 9 months to see how the drug ofatumumab affects microglia, the brain's immune cells. Researchers used special PET scans and blood tests to track changes. The goal was to understand how the drug works in the brain…

This completed survey looked at whether healthcare professionals and people with multiple sclerosis (or their caregivers) understand the safety steps needed when using the drug Mayzent (siponimod). Over 300 participants from Europe answered questions about proper use, side effect…